Analysts at MarketsandMarkets expect the AI healthcare sector to grow at a 38.6% CAGR, topping $110 billion by 2030. Accenture goes even further, estimating AI could inject another $461 billion in ...

Council approves conclusions ‘Towards the EU strategy on AI in science’ calling for a comprehensive strategy to boost the ...

Although still in its infancy, this technology has already shown remarkable effectiveness in detecting and treating cancer, ...

The global AI In Healthcare Market size is projected to be valued at USD 26.6 Billion in 2024 and reach USD 187.7 billion by 2030, growing at ...

The FDA and NIH recently announced plans to phase out animal testing requirements for some therapies. While organoid and AI ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

Lantern Pharma's Q1 2025 earnings reveal clinical progress, AI commercialization plans, and financial discipline.

Stuart J. Schnitt, MD, discussed how AI enhances cancer diagnoses and the need for professional oversight, ethical clarity, and equitable adoption.

We recently published a list of the 10 Most Popular AI Stocks to Avoid Now. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.

GE HealthCare (Nasdaq: GEHC) today announced the launch of its CleaRecon DL technology for enhancing CBCT imaging.